Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

Real-world retrospective cohort study ARCTIC shows burden of comorbidities in Swedish COPD versus non-COPD patients.

Ställberg B, Janson C, Larsson K, Johansson G, Kostikas K, Gruenberger JB, Gutzwiller FS, Jorgensen L, Uhde M, Lisspers K.

NPJ Prim Care Respir Med. 2018 Sep 10;28(1):33. doi: 10.1038/s41533-018-0101-y.

2.

 Identifying the associated risks of pneumonia in COPD patients: ARCTIC an observational study.

Janson C, Johansson G, Ställberg B, Lisspers K, Olsson P, Keininger DL, Uhde M, Gutzwiller FS, Jörgensen L, Larsson K.

Respir Res. 2018 Sep 10;19(1):172. doi: 10.1186/s12931-018-0868-y.

3.

Capturing Exacerbations of Chronic Obstructive Pulmonary Disease with EXACT. A Subanalysis of FLAME.

Frent SM, Chapman KR, Larbig M, Mackay A, Fogel R, Gutzwiller FS, Shen S, Patalano F, Banerji D, Kostikas K, Wedzicha JA.

Am J Respir Crit Care Med. 2019 Jan 1;199(1):43-51. doi: 10.1164/rccm.201801-0038OC.

4.

Factors associated with appropriate inhaler use in patients with COPD - lessons from the REAL survey.

Price D, Keininger DL, Viswanad B, Gasser M, Walda S, Gutzwiller FS.

Int J Chron Obstruct Pulmon Dis. 2018 Feb 26;13:695-702. doi: 10.2147/COPD.S149404. eCollection 2018. Erratum in: Int J Chron Obstruct Pulmon Dis. 2018 Jul 25;13:2253-2254.

5.

Economic burden of COPD in a Swedish cohort: the ARCTIC study.

Lisspers K, Larsson K, Johansson G, Janson C, Costa-Scharplatz M, Gruenberger JB, Uhde M, Jorgensen L, Gutzwiller FS, Ställberg B.

Int J Chron Obstruct Pulmon Dis. 2018 Jan 11;13:275-285. doi: 10.2147/COPD.S149633. eCollection 2018.

6.

Indacaterol/glycopyrronium is cost-effective compared to salmeterol/fluticasone in COPD: FLAME-based modelling in a Swedish population.

Bjermer L, van Boven JFM, Costa-Scharplatz M, Keininger DL, Gutzwiller FS, Lisspers K, Mahon R, Olsson P, Roche N.

Respir Res. 2017 Dec 11;18(1):206. doi: 10.1186/s12931-017-0688-5.

7.

Cost Effectiveness of Sucroferric Oxyhydroxide Compared with Sevelamer Carbonate in the Treatment of Hyperphosphataemia in Patients Receiving Dialysis, from the Perspective of the National Health Service in Scotland.

Gutzwiller FS, Pfeil AM, Ademi Z, Blank PR, Braunhofer PG, Szucs TD, Schwenkglenks M.

Pharmacoeconomics. 2015 Dec;33(12):1311-24. doi: 10.1007/s40273-015-0320-9.

8.

End-of-life costs of medical care for advanced stage cancer patients.

Kovacević A, Dragojević-Simić V, Rancić N, Jurisević M, Gutzwiller FS, Matter-Walstra K, Jakovljević M.

Vojnosanit Pregl. 2015 Apr;72(4):334-41. Erratum in: Vojnosanit Pregl. 2015 Jul;72(7):656. Gutzwiller, Florian [corrected to Gutzwiller, Florian S].

PMID:
26040179
9.

A Cost-effectiveness Analysis of Ferric Carboxymaltose in Patients With Iron Deficiency and Chronic Heart Failure in Spain.

Comín-Colet J, Rubio-Rodríguez D, Rubio-Terrés C, Enjuanes-Grau C, Gutzwiller FS, Anker SD, Ponikowski P.

Rev Esp Cardiol (Engl Ed). 2015 Oct;68(10):846-51. doi: 10.1016/j.rec.2014.10.010. Epub 2015 Jan 28.

PMID:
25649970
10.

Cost Comparison Among First Line Monoclonal Antibodies-Based Oncology Treatment Protocols.

Jakovljevic M, Gutzwiller FS, Schwenkglenks M, Milovanovic O, Rancic N, Varjacic M, Stojadinovic D, Dagovic A, Matter-Walstra K.

Value Health. 2014 Nov;17(7):A629. doi: 10.1016/j.jval.2014.08.2247. Epub 2014 Oct 26. No abstract available.

11.

Determinants of quality of life of patients with heart failure and iron deficiency treated with ferric carboxymaltose: FAIR-HF sub-analysis.

Gutzwiller FS, Pfeil AM, Comin-Colet J, Ponikowski P, Filippatos G, Mori C, Braunhofer PG, Szucs TD, Schwenkglenks M, Anker SD.

Int J Cardiol. 2013 Oct 9;168(4):3878-83. doi: 10.1016/j.ijcard.2013.06.045. Epub 2013 Jul 17.

12.

Health economic assessment of ferric carboxymaltose in patients with iron deficiency and chronic heart failure based on the FAIR-HF trial: an analysis for the UK.

Gutzwiller FS, Schwenkglenks M, Blank PR, Braunhofer PG, Mori C, Szucs TD, Ponikowski P, Anker SD.

Eur J Heart Fail. 2012 Jul;14(7):782-90. doi: 10.1093/eurjhf/hfs083. Epub 2012 Jun 11.

13.
14.

A questionnaire on treatment satisfaction and disease specific knowledge among patients with acute coronary syndrome. II: Insights for patient education and quality improvement.

Frick U, Gutzwiller FS, Maggiorini M, Christen S.

Patient Educ Couns. 2012 Mar;86(3):366-71. doi: 10.1016/j.pec.2011.06.004. Epub 2011 Jun 29.

PMID:
21719236
15.

FERGIcor, a randomized controlled trial on ferric carboxymaltose for iron deficiency anemia in inflammatory bowel disease.

Evstatiev R, Marteau P, Iqbal T, Khalif IL, Stein J, Bokemeyer B, Chopey IV, Gutzwiller FS, Riopel L, Gasche C; FERGI Study Group.

Gastroenterology. 2011 Sep;141(3):846-853.e1-2. doi: 10.1053/j.gastro.2011.06.005. Epub 2011 Jun 12.

PMID:
21699794
16.

In-hospital delay increases the risk of perforation in adults with appendicitis.

Busch M, Gutzwiller FS, Aellig S, Kuettel R, Metzger U, Zingg U.

World J Surg. 2011 Jul;35(7):1626-33. doi: 10.1007/s00268-011-1101-z.

PMID:
21562871
17.

[Botulism: prevention, clinical diagnostics, therapy and possible threat].

Gutzwiller FS, Steffen R, Mathys P, Walser S, Schmid H, Mütsch M.

Dtsch Med Wochenschr. 2008 Apr;133(16):840-5. doi: 10.1055/s-2008-1075658. Review. German.

PMID:
18398794
18.

Do citizens have minimum medical knowledge? A survey.

Bachmann LM, Gutzwiller FS, Puhan MA, Steurer J, Steurer-Stey C, Gigerenzer G.

BMC Med. 2007 May 31;5:14.

Supplemental Content

Loading ...
Support Center